logo-loader
viewAdvanced Oncotherapy PLC

Total Voting Rights and Directors' Shareholdings

/**/ ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: #954F72 } .ai{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.ai{}p.bo{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin: 0cm; margin-bottom: .0001pt; text-align: right}span.bp{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}p.bq{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin: 0cm; margin-bottom: .0001pt; text-align: center}span.br{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}span.bi{color:black}p.bs{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin: 0cm; margin-bottom: .0001pt; text-align: center}span.bt{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.bu{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black} p.bv{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: center}p.bw{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal}p.bx{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: normal}p.by{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm}table.bz{margin-left:-5.4pt;border-collapse:collapse;border:none}td.bd{width:144.9pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.bb{width:95.5pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}p.ca{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: right}td.ba{width:116.8pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.az{width:144.9pt;border:solid windowtext 1.0pt;border-top: none;padding:0cm 5.4pt 0cm 5.4pt} td.ax{width:95.5pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.cb{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin-bottom: 0cm; text-align: right}td.aw{width:116.8pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.av{width:95.5pt;border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.au{width:116.8pt;border-top:none;border-left:none; border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}table.cc{width:510.35pt;margin-left:-23.3pt;border-collapse:collapse}td.ar{width:215.7pt;padding:0cm 5.4pt 0cm 5.4pt}p.cd{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; margin-left: 7.1pt; margin-right: 0cm; margin-top: 0cm}td.ap{width:258.95pt;padding:0cm 5.4pt 0cm 5.4pt}span.aq{font-size:9.0pt;color:black} p.ce{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:0cm;margin-bottom:0cm; margin-left:7.1pt;margin-bottom:.0001pt;line-height:normal}td.an{width:311.7pt;padding:0cm 5.4pt 0cm 5.4pt}td.am{width:166.05pt;padding:0cm 5.4pt 0cm 5.4pt}span.al{color:black;background:white}td.ak{padding:0cm 0cm 0cm 0cm} /**/
RNS Number : 1304K
Advanced Oncotherapy PLC
27 August 2019
 

27 August 2019

 

ADVANCED ONCOTHERAPY PLC

 

("Advanced Oncotherapy" or the "Company") 

 

Total Voting Rights and Directors' Shareholdings

 

Advanced Oncotherapy (AIM: AVO), the developer of a next generation proton therapy system for cancer treatment confirms that, following Second Admission on 19 August 2019 as described in the Company's announcement of 7 August 2019, the Company's issued share capital consists of 230,226,094 Ordinary Shares with one voting right each.

 

The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares in the Company with voting rights is 230,226,094. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Directors' Shareholdings

 

Set out below are details of the Directors' interests in Ordinary Shares following Second Admission.

 

Director

Number of
Ordinary Shares

% of current issued
share capital

Mr. Chunlin Han, Mrs. RenHua Zhang and Dr Yuelong Huang*

45,000,000

19.55

Mr Michael Bradfield

7,193,240

3.12

Michael Sinclair & Family

7,469,660

3.24

Mr Gabriel Urwitz**

6,551,289

2.85

Dr P N Plowman

4,042,804

1.76

Dr Enrico C Vanni

2,126,361

0.92

Mr Nicolas Serandour

1,760,467

0.76

Mr Steve Myers

783,902

0.34

Mr Hans Van Celsing

142,500

0.06

 

*Liquid Harmony Ltd holds 45,000,000 Ordinary Shares and is represented by Mr. Chunlin Han, Mrs. RenHua Zhang and Dr Yuelong Huang, all Non-Executive Directors.

 

**Gabriel Urwitz, Non-Executive Director, holds 62,500 Ordinary Shares in his own name. In addition, AB Segulah, of which Mr Urwitz is a director and shareholder, holds 6,488,789 Ordinary Shares. As a result, AB Segulah and Mr Urwitz in aggregate have a total interest of 6,551,289 Ordinary Shares, equivalent to 2.85 per cent. of the Company's current issued share capital.

 

Defined terms used in this announcement shall have the same meaning as in the announcement of 7 August 2019 unless otherwise defined herein. 

 

 

Advanced Oncotherapy Plc

www.avoplc.com

Dr. Michael Sinclair, Executive Chairman

Tel: +44 (0)20 3617 8728

Nicolas Serandour, CEO

 

 




Allenby Capital Limited (Nominated Adviser & Joint Broker)


Nick Athanas / Liz Kirchner / Nicholas Chambers

 

 

Tel: +44 (0)20 3328 5656



Stifel Nicolaus Europe (Joint Broker)


Jonathan Senior

 

 

Tel: +44 (0)20 7710 7600



Walbrook PR (Financial PR & IR)

Tel: +44 (0)20 7933 8780 or [email protected]

Paul McManus / Anna Dunphy

Mob: +44 (0)7980 541 893 / Mob: +44 (0)7876 741 001




 

About Advanced Oncotherapy Plc www.avoplc.com

 

Advanced Oncotherapy is a provider of particle therapy in the treatment of cancer, which harnesses the very best in modern technology. Advanced Oncotherapy's R&D team, ADAM, in Geneva, focuses on the development of a proprietary proton accelerator - LIGHT (Linac Image Guided Hadron Technology). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a compact and truly modular unit, offering significant cost advantages. LIGHT also delivers proton beams in a way that facilitates greater precision and electronic control, which are not achievable with currently available alternative technologies.

 

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology, offering better health outcomes and lower treatment related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton or particle therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of cutting edge, cost-effective systems for particle therapy.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCPGURPRUPBGQW

Quick facts: Advanced Oncotherapy PLC

Price: 38

Market: LSE
Market Cap: £90.29 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tertiary Minerals, Advanced Oncotherapy among Alan Green's 2018 stocks to watch

Brand Communications' Alan Green highlights his small cap stocks to watch in 2018. First on Alan's hit list is Tertiary Minerals (LON:TYM). Tertiary’s share price has been on a good run recently since it announced they'd signed an MoU with global commodities group Possehl to enter...

on 27/12/17